XCUR vs. THAR, SNGX, LGVN, ENSC, GTBP, ARTL, LIPO, EVOK, CPHI, and DRUG
Should you be buying Exicure stock or one of its competitors? The main competitors of Exicure include Tharimmune (THAR), Soligenix (SNGX), Longeveron (LGVN), Ensysce Biosciences (ENSC), GT Biopharma (GTBP), Artelo Biosciences (ARTL), Lipella Pharmaceuticals (LIPO), Evoke Pharma (EVOK), China Pharma (CPHI), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical preparations" industry.
Tharimmune (NASDAQ:THAR) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, community ranking, institutional ownership, media sentiment, dividends, valuation and profitability.
Tharimmune has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. Comparatively, Exicure has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.
In the previous week, Tharimmune had 3 more articles in the media than Exicure. MarketBeat recorded 4 mentions for Tharimmune and 1 mentions for Exicure. Tharimmune's average media sentiment score of 1.89 beat Exicure's score of 1.09 indicating that Exicure is being referred to more favorably in the news media.
Tharimmune's return on equity of 0.00% beat Exicure's return on equity.
Exicure has higher revenue and earnings than Tharimmune.
Exicure received 9 more outperform votes than Tharimmune when rated by MarketBeat users.
1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 2.4% of Tharimmune shares are owned by company insiders. Comparatively, 8.4% of Exicure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Exicure beats Tharimmune on 8 of the 10 factors compared between the two stocks.
Get Exicure News Delivered to You Automatically
Sign up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XCUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
